Revisiting Androgen Receptor Signaling in Breast Cancer

Area of Science:

• Oncology
• Endocrinology
• Molecular Biology

Background:

• Aberrant estrogen receptor (ER) signaling is a key factor in breast cancer development.
• The androgen receptor (AR), a steroid nuclear receptor, is frequently found in breast cancer and is a potential therapeutic target.
• Historical use of androgens for breast cancer treatment declined due to side effects and concerns about conversion to estrogens.

Purpose of the Study:

• To review current understanding of AR biology in breast cancer.
• To discuss recent advances and ongoing investigations into AR-directed therapies.
• To explore the context-specific roles of AR in different breast cancer subtypes.

Main Methods:

• Literature review of preclinical and clinical studies on AR in breast cancer.
• Analysis of recent molecular advances, including selective androgen receptor modulators (SARMs).
• Synthesis of evidence regarding AR agonists and antagonists in breast cancer treatment.

Main Results:

• Preclinical studies on AR in breast cancer have produced conflicting results.
• AR's role appears to be context-specific, potentially differing between ER-positive and ER-negative breast cancers.
• Renewed interest in AR targeting is driven by new therapeutic strategies like SARMs.

Conclusions:

• Androgen receptor signaling in breast cancer is complex and not fully understood.
• Further research is needed to clarify AR's divergent actions in ER-positive versus ER-negative disease.
• AR-directed therapies, including agonists and antagonists, warrant continued clinical investigation.